Rémi Rosière

Rémi Rosière

Auto-generated profile, based on publicly available information

Rémi Rosière

Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), 1050 Ixelles, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
MWMatthias Van Woensel
Matthias Van Woensel
NWNathalie Wauthoz
Nathalie Wauthoz
RRRémi Rosière
Rémi Rosière
VMVéronique Mathieu
Véronique Mathieu
RKRobert Kiss
Robert Kiss
SVSteven De Vleeschouwer
Steven De Vleeschouwer

17 January 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RRRémi Rosière
Rémi Rosière
MWMatthias Van Woensel
Matthias Van Woensel
MGMichel Gelbcke
Michel Gelbcke
VMVéronique Mathieu
Véronique Mathieu
JHJulien Hecq
Julien Hecq
NWNathalie Wauthoz
Nathalie Wauthoz

14 August 2013 in Cancers
Verified
Journal Article
Open access
PDF file
MWMatthias Van Woensel
Matthias Van Woensel
NWNathalie Wauthoz
Nathalie Wauthoz
RRRémi Rosière
Rémi Rosière
KAKarim Amighi
Karim Amighi
Véronique MathieuVéronique Mathieu
Véronique Mathieu
SVSteven De Vleeschouwer
Steven De Vleeschouwer
Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months. Infiltration of glioma cells into the brain parenchyma, and the blood-brain barrier are important hurdles to further increase the efficacy of classic therapeutic tools. Local administration methods of therapeutic agents, such as convection enhanced delivery and intracerebral injections, are often associated with adverse events. The intranasal pathway has been proposed as a non-invasive alternative route to deliver therapeutics to the brain. This route will bypass the blood-brain barrier and limit systemic side effects. Upon presentation at the nasal cavity, pharmacological agents reach the brain via the olfactory and trigeminal nerves. Recently, formulations have been developed to further enhance this nose-to-brain transport, mainly with the use of nanoparticles. In this review, the focus will be on formulations of pharmacological agents, which increase the nasal permeation of hydrophilic agents to the brain, improve delivery at a constant and slow release rate, protect therapeutics from degradation along the pathway, increase mucoadhesion, and facilitate overall nasal transport. A mounting body of evidence is accumulating that the underexplored intranasal delivery route might represent a major breakthrough to combat glioblastoma.

1 December 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VLVincent Levet
Vincent Levet
RRRémi Rosière
Rémi Rosière
RMRomain Merlos
Romain Merlos
LFLuca Fusaro
Luca Fusaro
GBGilles Berger
Gilles Berger
NWNathalie Wauthoz
Nathalie Wauthoz

1 June 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
GPGabrielle Pilcer
Gabrielle Pilcer
RRRémi Rosière
Rémi Rosière
KTKarl Traina
Karl Traina
TSThami Sebti
Thami Sebti
FVFrancis Vanderbist
Francis Vanderbist
KAKarim Amighi
Karim Amighi

7 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
RRRémi Rosière
Rémi Rosière
TBThierry Berghmans
Thierry Berghmans
PVPaul De Vuyst
Paul De Vuyst
KAKarim Amighi
Karim Amighi
NWNathalie Wauthoz
Nathalie Wauthoz
Despite new treatment modalities, including targeted therapies and checkpoint inhibitors, cytotoxic chemotherapy remains central in the care of patients with lung tumors. Use of the pulmonary route to deliver chemotherapy has been proved to be feasible and safe in phase I, Ib/IIa and II trials for lung tumors, with the administration of drug doses to the lungs without prior distribution in the organism. The severe systemic toxicities commonly observed with conventional systemic chemotherapy are consequently reduced. However, development has failed in phase II at best. This review first focuses on the causes of failure of inhaled chemotherapy. It then presents new promising technologies able to take up the current challenges. These technologies include the use of a dry powder inhaler or a smart nebulizer with advanced drug formulations such as controlled-release formulations and nanomedicine. Finally, the potential position of inhaled chemotherapy in patient care is discussed and some indications are proposed based on the literature.